These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 20055559)
1. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559 [TBL] [Abstract][Full Text] [Related]
2. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585 [TBL] [Abstract][Full Text] [Related]
3. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Singh P; Gupta U; Asthana A; Jain NK Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158 [TBL] [Abstract][Full Text] [Related]
5. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents]. Kong SY; Tang GT; Pei YY; Jiang YY Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828 [TBL] [Abstract][Full Text] [Related]
6. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Patri AK; Kukowska-Latallo JF; Baker JR Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254 [TBL] [Abstract][Full Text] [Related]
7. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822 [TBL] [Abstract][Full Text] [Related]
9. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Khandare JJ; Jayant S; Singh A; Chandna P; Wang Y; Vorsa N; Minko T Bioconjug Chem; 2006; 17(6):1464-72. PubMed ID: 17105225 [TBL] [Abstract][Full Text] [Related]
10. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Han L; Huang R; Liu S; Huang S; Jiang C Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates. Zhang Y; Sun Y; Xu X; Zhang X; Zhu H; Huang L; Qi Y; Shen YM J Med Chem; 2010 Apr; 53(8):3262-72. PubMed ID: 20350006 [TBL] [Abstract][Full Text] [Related]
12. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Kono K; Kojima C; Hayashi N; Nishisaka E; Kiura K; Watarai S; Harada A Biomaterials; 2008 Apr; 29(11):1664-75. PubMed ID: 18194811 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583 [TBL] [Abstract][Full Text] [Related]
14. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells. Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350 [TBL] [Abstract][Full Text] [Related]
15. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Han L; Li J; Huang S; Huang R; Liu S; Hu X; Yi P; Shan D; Wang X; Lei H; Jiang C Biomaterials; 2011 Apr; 32(11):2989-98. PubMed ID: 21277017 [TBL] [Abstract][Full Text] [Related]
16. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. He H; Li Y; Jia XR; Du J; Ying X; Lu WL; Lou JN; Wei Y Biomaterials; 2011 Jan; 32(2):478-87. PubMed ID: 20934215 [TBL] [Abstract][Full Text] [Related]
17. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Gajbhiye V; Vijayaraj Kumar P; Tekade RK; Jain NK Eur J Med Chem; 2009 Mar; 44(3):1155-66. PubMed ID: 18760863 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system. Sideratou Z; Kontoyianni C; Drossopoulou GI; Paleos CM Bioorg Med Chem Lett; 2010 Nov; 20(22):6513-7. PubMed ID: 20888223 [TBL] [Abstract][Full Text] [Related]
19. Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats. Kaminskas LM; McLeod VM; Ascher DB; Ryan GM; Jones S; Haynes JM; Trevaskis NL; Chan LJ; Sloan EK; Finnin BA; Williamson M; Velkov T; Williams ED; Kelly BD; Owen DJ; Porter CJ Mol Pharm; 2015 Feb; 12(2):432-43. PubMed ID: 25485615 [TBL] [Abstract][Full Text] [Related]
20. PEGylated dendrimers with core functionality for biological applications. Guillaudeu SJ; Fox ME; Haidar YM; Dy EE; Szoka FC; Fréchet JM Bioconjug Chem; 2008 Feb; 19(2):461-9. PubMed ID: 18173227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]